Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib

Elona Malja; Asha Kandathil; Fangyu Peng

doi:10.1007/s13139-023-00824-3

Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib

Elona Malja, Asha Kandathil, Fangyu Peng

Research output: Contribution to journal › Article › peer-review

Abstract

Redifferentiation therapy with Dabrafenib (a BRAF inhibitor) and Trametinib (a MEK inhibitor) restores radioiodine avidity of radioiodine-refractory papillary thyroid carcinoma (PTC). A 50-year-old man was diagnosed with radioiodine-refractory PTC pulmonary metastasis post prior total thyroidectomy and radioiodine ablation. The patient was treated with Dabrafenib and Trametinib, followed by second radioiodine ablation with I-131 sodium iodine. Diffuse increased radioiodine uptake by pulmonary metastasis was visualized on post ablation whole body scan. Response to second radioiodine ablation was demonstrated by decrease in size of pulmonary nodules seen on chest CT, along with decrease of thyroglobulin level.

Original language	English (US)
Pages (from-to)	92-94
Number of pages	3
Journal	Nuclear Medicine and Molecular Imaging
Volume	58
Issue number	2
DOIs	https://doi.org/10.1007/s13139-023-00824-3
State	Published - Apr 2024

Keywords

BRAF-V600E mutation
Dabrafenib
Papillary thyroid carcinoma
Radioiodine
Trametinib

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s13139-023-00824-3

Cite this

@article{57d39a2bbf624b44ad94edbd0f39f514,

title = "Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib",

abstract = "Redifferentiation therapy with Dabrafenib (a BRAF inhibitor) and Trametinib (a MEK inhibitor) restores radioiodine avidity of radioiodine-refractory papillary thyroid carcinoma (PTC). A 50-year-old man was diagnosed with radioiodine-refractory PTC pulmonary metastasis post prior total thyroidectomy and radioiodine ablation. The patient was treated with Dabrafenib and Trametinib, followed by second radioiodine ablation with I-131 sodium iodine. Diffuse increased radioiodine uptake by pulmonary metastasis was visualized on post ablation whole body scan. Response to second radioiodine ablation was demonstrated by decrease in size of pulmonary nodules seen on chest CT, along with decrease of thyroglobulin level.",

keywords = "BRAF-V600E mutation, Dabrafenib, Papillary thyroid carcinoma, Radioiodine, Trametinib",

author = "Elona Malja and Asha Kandathil and Fangyu Peng",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Korean Society of Nuclear Medicine 2023.",

year = "2024",

month = apr,

doi = "10.1007/s13139-023-00824-3",

language = "English (US)",

volume = "58",

pages = "92--94",

journal = "Nuclear Medicine and Molecular Imaging",

issn = "1869-3474",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib

AU - Malja, Elona

AU - Kandathil, Asha

AU - Peng, Fangyu

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Korean Society of Nuclear Medicine 2023.

PY - 2024/4

Y1 - 2024/4

N2 - Redifferentiation therapy with Dabrafenib (a BRAF inhibitor) and Trametinib (a MEK inhibitor) restores radioiodine avidity of radioiodine-refractory papillary thyroid carcinoma (PTC). A 50-year-old man was diagnosed with radioiodine-refractory PTC pulmonary metastasis post prior total thyroidectomy and radioiodine ablation. The patient was treated with Dabrafenib and Trametinib, followed by second radioiodine ablation with I-131 sodium iodine. Diffuse increased radioiodine uptake by pulmonary metastasis was visualized on post ablation whole body scan. Response to second radioiodine ablation was demonstrated by decrease in size of pulmonary nodules seen on chest CT, along with decrease of thyroglobulin level.

AB - Redifferentiation therapy with Dabrafenib (a BRAF inhibitor) and Trametinib (a MEK inhibitor) restores radioiodine avidity of radioiodine-refractory papillary thyroid carcinoma (PTC). A 50-year-old man was diagnosed with radioiodine-refractory PTC pulmonary metastasis post prior total thyroidectomy and radioiodine ablation. The patient was treated with Dabrafenib and Trametinib, followed by second radioiodine ablation with I-131 sodium iodine. Diffuse increased radioiodine uptake by pulmonary metastasis was visualized on post ablation whole body scan. Response to second radioiodine ablation was demonstrated by decrease in size of pulmonary nodules seen on chest CT, along with decrease of thyroglobulin level.

KW - BRAF-V600E mutation

KW - Dabrafenib

KW - Papillary thyroid carcinoma

KW - Radioiodine

KW - Trametinib

UR - http://www.scopus.com/inward/record.url?scp=85170044154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170044154&partnerID=8YFLogxK

U2 - 10.1007/s13139-023-00824-3

DO - 10.1007/s13139-023-00824-3

M3 - Article

C2 - 38510823

AN - SCOPUS:85170044154

SN - 1869-3474

VL - 58

SP - 92

EP - 94

JO - Nuclear Medicine and Molecular Imaging

JF - Nuclear Medicine and Molecular Imaging

IS - 2

ER -

Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this